SEC Comment Letter 0000000000-23-006658 to AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: June 22, 2023 · CIK: 0001644963 · Accession: 0000000000-23-006658
AI Filing Summary & Sentiment
File numbers found in text: 333-272730
Letter
United States securities and exchange commission logo June 22, 2023 Alexandra MacLean, M.D. Chief Executive Officer Avenue Therapeutics, Inc 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 Re:Avenue Therapeutics, Inc Registration Statement on Form S-3 Filed June 16, 2023 File No. 333-272730 Dear Alexandra MacLean: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David S. Wolpa
Show Raw Text
United States securities and exchange commission logo
June 22, 2023
Alexandra MacLean, M.D.
Chief Executive Officer
Avenue Therapeutics, Inc
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
Re:Avenue Therapeutics, Inc
Registration Statement on Form S-3
Filed June 16, 2023
File No. 333-272730
Dear Alexandra MacLean:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David S. Wolpa